Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Venetoclax Shows Impressive Activity in Relapsed/Refractory Waldenström Macroglobulinemia

January 19th 2022

Venetoclax proved to be safe and highly active when used in patients with relapsed or refractory Waldenström macroglobulinemia, including those who previously received BTK inhibitors and those harboring CXCR4 mutations.

Chronic Myeloid Leukemia: Assessing Treatment Response

January 19th 2022

Key opinion leader perspectives on assessing a patient’s response to therapy for chronic myeloid leukemia.

Chromosomal Abnormalities and Genetic Alterations in CML

January 19th 2022

Shared insight on chromosomal abnormalities and genetic alterations that influence the disease course and management of CML.

Dr. Phillips Discusses Ongoing Trials in MCL

January 17th 2022

Tycel Jovelle Phillips, MD, discusses ongoing trials in mantle cell lymphoma.

Intensive Chemotherapy Falls a Few Steps Behind in Leukemia and Lymphoma

January 15th 2022

Naval Daver, MD, discusses the latest developments in acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and follicular lymphoma.

Rapid Readout: Pirtobrutinib, A Highly Selective, Noncovalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

January 14th 2022

Anthony Mato, MD, discusses updated efficacy and safety results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor, pirtobrutinib, in patients with previously treated CLL/SLL that was presented at the American Society of Hematology 2021 Annual Meeting.

Incorporation of Chemotherapy-Free Regimens Improve Outcomes in Hematologic Malignancies

January 13th 2022

Thomas Kipps, MD, PhD, discussed navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS.

Polatuzumab Vedotin Plus R-CHP Emerges as Potential New Standard for Newly Diagnosed DLBCL

January 11th 2022

John M. Burke, MD, highlights the benefits derived with polatuzumab vedotin plus R-CHP and projects the next steps for the regimen.

FDA Grants Breakthrough Device Designation to BNT200 for Anxiety/Depression in AML

January 11th 2022

The FDA has granted a breakthrough device designation to BNT200, a prescription-only digital therapeutic to leverage in the treatment of anxiety and depressive symptoms created by psychological stressors experienced by adults with acute myeloid leukemia who are hospitalized and undergoing high-intensity induction chemotherapy.

Dr. Riedell on Unique Data Points from an Analysis in MCL

January 11th 2022

Peter Riedell, MD, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma.

Aspacytarabine Shows Efficacy, Safety in Newly Diagnosed AML Unfit for Intensive Therapy

January 10th 2022

The novel antimetabolite aspacytarabine was found to produce a complete remission rate of 37% in adult patients with newly diagnosed acute myeloid leukemia who are unfit for intensive therapy.

Dr. Sallman on the Responses to PRGN-3006 in Select AML and Higher-Risk MDS

January 10th 2022

David Sallman, MD, discusses responses achieved a first-in-human dose escalation/dose expansion phase 1/1b clinical trial of an UltraCAR-T agent, PRGN-3006, in patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome with hypomethylating agent failure.

CA-4948 Shows Early Activity, Tolerability in Relapsed/Refractory AML and High-Risk MDS

January 7th 2022

CA-4948 monotherapy was found to have preliminary activity with acceptable safety and tolerability in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes, according to updated data from an ongoing phase 1/2 trial.

Dr. Matthews on the Efficacy of CPX-351 Vs Venetoclax/Azacitidine in AML

January 7th 2022

Andrew Matthews, MD, discusses the efficacy of CPX-351 vs venetoclax plus azacitidine in acute myeloid leukemia.

Dr. Jain on the Utility of UCART22 in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

January 7th 2022

Nitin Jain, MD, discusses the preliminary results from the phase 1 BALLI-01 study, which investigated UCART22, a genetically modified allogeneic T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Q&A: Early Treatment of CLL

January 5th 2022

Richard R. Furman, MD, and Nitin Jain, MD, share insight on the evolving treatment landscape of CLL, particularly for treatment in early line settings.

Q&A: Modifying and Switching Therapies in CLL

January 5th 2022

Nitin Jain, MD, and Richard R. Furman, MD, discuss the standard treatment criteria for CLL and answer audience questions on the appropriate circumstances to adjust, switch, and discontinue therapy.

Novel Treatments for the Management of CLL

January 5th 2022

Nitin Jain, MD, comments on the use of novel treatment strategies, including CAR T-cell therapy, being evaluated to treat patients with CLL.

Examining the Development of T-cell Acute Lymphoblastic Leukemia

December 31st 2021

Despite advances in treatments for T-cell acute lymphoblastic leukemia, patients have an extremely poor prognosis, highlighting the need to explore the genetic components that lead to the formation of the disease, as well as the need to discover new targeted therapeutic approaches and treatment resistance

FDA Grants Fast Track Status to CYNK-001 for AML

December 27th 2021

The FDA has granted Fast Track Designation to CYNK-001, a non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, for the potential treatment of patients with acute myeloid leukemia.